Fig 2: Validation of TGFBI and NFKB2 as putative VHL targeted proteins. (A) Western blot of TGFBI and NFKB2 in 786-O-Ctrl and 786-O-VHL cells after MG132 treatment. (B) Western blot of TGFBI in the conditioned medium of 786-O-Ctrl and 786-O-VHL cells. (C) Cell adhesion assay of 786-O-Ctrl and 786-O-VHL cells to fibronectin-coated plate. ** p < 0.01 by Student’s t-test. (D) Scatter plot of normalized VHL and NFKB2 protein expression with data from the ccRCC CPTAC study. Pearson correlation coefficient ρ and p value are shown. (E) Immunoassay of the endogenous VHL–NFKB2 association in 786-O-Ctrl and 786-O-VHL cells, assessed by immunoprecipitation (IP) with immunoglobulin G (IgG), as a control, or with anti-NFKB2, followed by immunoblot analysis with anti-NFKB2 or anti-VHL. (F) Western blot of NFKB2 and VHL in HEK293T cells transiently transfected with NFKB2 (wild type), NFKB2 (K72R mutant) and/or VHL plasmids.

Fig 3: Rates of antimicrobial resistance (resistance data from the ATLAS database [53], except for the UAE [57]) or nonsusceptibility (non-susceptibility data from Oman presented to 1 decimal place but presented to the nearest whole number in the publication [20]) and difficult-to-treat resistance (DTR data from the ATLAS database [53]) among P. aeruginosa (2016–2021). Rates of antimicrobial resistance or non-susceptibility were presented as the percentage of resistant or non-susceptible P. aeruginosa (determined using CLSI breakpoints [64]) of the total isolates collected. DTR was defined as resistance to >1 antimicrobial in each of the following classes: cephalosporins (ceftazidime, cefepime or ceftriaxone), carbapenems (imipenem, meropenem, doripenem or ertapenem), and quinolones (ciprofloxacin or levofloxacin). Total isolate numbers [years of collection] were: KW, 757 (CZA, CST: 721) [2016–2021]; OM, 2362 [2016 and 2017]; QA, 116 [2019–2021]; SA, 160 (CZA, CST: 140) [2016, 2018–2021]; UAE, 9402 [2020]; IN, 1405 (CZA and CST: 1365) [2016, 2018–2021]; PK, 36 [2016 and 2017]; EMR incl Greece (Greece, Jordan, Israel, and Turkey), 2561 (CZA and CST: 2413) [2016–2021]; S. Europe excl Greece (Croatia, Italy, Portugal, Serbia and Spain), 6185 (CZA and CST: 5063) [2016–2021]; North America (Canada and United States), 5601 (CZA and CST: 4876) [2016–2021]; Latin America (Argentina, Brazil, Chile, Colombia, Costa Rica, Dominican Republic, Mexico, Panama and Venezuela), 6380 (CZA and CST: 5808) [2016–2021]; and Southeast Asia (Malaysia, Philippines, Singapore, Thailand and Vietnam), 2126 (CZA and CST: 2027) [2016–2021]). AMK, amikacin; CZA, ceftazidime-avibactam; CST, colistin; DTR, difficult-to-treat resistance; EMR, Eastern Mediterranean region; excl, excluding; IN, India; incl, including; KW, Kuwait; MEM, meropenem; OM, Oman; PK, Pakistan; QA, Qatar; S., Southern; SA, Saudi Arabia; TZP, piperacillin-tazobactam; and UAE, United Arab Emirates. -, no data collected for these antimicrobial agents in the selected countries